

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending June 30, 2010 and 2009**  
**(unaudited)**  
**(\$ in millions)**

	Q2 2010	Q2 2009	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2010	YTD 2009	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
United States	\$636	\$671	(5%)	(5%)	\$1,246	\$1,293	(4%)	(4%)
International	722	747	(3%)	(5%)	1,474	1,377	7%	1%
<b>Total BioScience</b>	<b>\$1,358</b>	<b>\$1,418</b>	<b>(4%)</b>	<b>(5%)</b>	<b>\$2,720</b>	<b>\$2,670</b>	<b>2%</b>	<b>(1%)</b>
<b>Medication Delivery</b>								
United States	\$612	\$546	12%	12%	\$1,191	\$1,060	12%	12%
International	627	588	7%	0%	1,230	1,109	11%	1%
<b>Total Medication Delivery - Adjusted<sup>1</sup></b>	<b>\$1,239</b>	<b>\$1,134</b>	<b>9%</b>	<b>6%</b>	<b>\$2,421</b>	<b>\$2,169</b>	<b>12%</b>	<b>7%</b>
COLLEAGUE infusion pump charge <sup>1</sup>					(213)			
<b>Total Medication Delivery - GAAP<sup>1</sup></b>	<b>\$1,239</b>	<b>\$1,134</b>	<b>9%</b>	<b>6%</b>	<b>\$2,208</b>	<b>\$2,169</b>	<b>2%</b>	<b>(3%)</b>
<b>Renal</b>								
United States	\$98	\$96	2%	2%	\$193	\$188	3%	3%
International	487	454	7%	1%	976	877	11%	3%
<b>Total Renal</b>	<b>\$585</b>	<b>\$550</b>	<b>6%</b>	<b>1%</b>	<b>\$1,169</b>	<b>\$1,065</b>	<b>10%</b>	<b>3%</b>
<b>Transfusion Therapies<sup>2</sup></b>								
United States	\$9	\$12	(25%)	(25%)	\$18	\$25	(28%)	(28%)
International	3	9	(67%)	(67%)	6	18	(67%)	(67%)
<b>Total Transfusion Therapies</b>	<b>\$12</b>	<b>\$21</b>	<b>(43%)</b>	<b>(43%)</b>	<b>\$24</b>	<b>\$43</b>	<b>(44%)</b>	<b>(44%)</b>
<b>Baxter International Inc.</b>								
United States	\$1,355	\$1,325	2%	2%	\$2,648	\$2,566	3%	3%
International	1,839	1,798	2%	(2%)	3,686	3,381	9%	1%
<b>Total Baxter - Adjusted<sup>1</sup></b>	<b>\$3,194</b>	<b>\$3,123</b>	<b>2%</b>	<b>0%</b>	<b>\$6,334</b>	<b>\$5,947</b>	<b>7%</b>	<b>2%</b>
COLLEAGUE infusion pump charge <sup>1</sup>					(213)			
<b>Total Baxter - GAAP<sup>1</sup></b>	<b>\$3,194</b>	<b>\$3,123</b>	<b>2%</b>	<b>0%</b>	<b>\$6,121</b>	<b>\$5,947</b>	<b>3%</b>	<b>(1%)</b>

<sup>1</sup> GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps from the U.S. market. Refer to page 16 for a reconciliation to GAAP measures.

<sup>2</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.